CJC-1295 with DAC

CJC-1295 with DAC Overview

CJC-1295 with Drug Affinity Complex (DAC) is a chemically stabilized, synthetic peptide analog designed to mimic the physiological functions of Growth Hormone-Releasing Hormone (GHRH). In a research environment, this peptide is primarily utilized to study the long-term modulation of the growth hormone axis. Unlike standard GHRH analogs that possess a half-life of mere minutes, the DAC-modified version is engineered to remain biologically active in the systemic circulation for several days.

The mechanism of action involves the peptide binding to the GHRH receptors located in the pituitary gland. This interaction initiates a signal transduction pathway that results in the secretion of growth hormone. Because the DAC modification allows the peptide to bond with serum albumin, it creates a stable reservoir of the compound. This ensures a more consistent stimulation of growth hormone, leading to higher cumulative levels of Insulin-like Growth Factor 1 (IGF-1) compared to shorter-acting secretagogues.

CJC-1295 with DAC Structure

Chemical Information

• Appearance: Pure white lyophilized powder
• Molecular Formula: C165H271N47O46
• Molecular Weight: Approximately 3647.9 grams per mole
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Lys(Maleimidopropionyl)-NH2
• Structure Solution Formula: Carbon 165, Hydrogen 271, Nitrogen 47, Oxygen 46 (C165 H271 N47 O46)
• Purity: 98 percent or higher

Attribute

Research Specification

Peptide Class

Growth Hormone Secretagogue

Modification

Drug Affinity Complex (DAC)

Carrier Affinity

Human Serum Albumin (HSA)

Biological Half-Life

6 to 8 Days

CJC-1295 with DAC Research

Stability and Long-Term Storage

As a lyophilized peptide, CJC-1295 with DAC exhibits high structural stability when maintained in a desiccated state. For long-term preservation, the compound should be kept at -20 degrees Celsius. Once reconstituted with a sterile aqueous solution, the peptide becomes more susceptible to deamidation and oxidation. It is recommended to store reconstituted solutions at 2 to 8 degrees Celsius and to use them within 30 days to maintain experimental accuracy.

Endocrine System Modulation

Research into CJC-1295 with DAC focus on its ability to maintain growth hormone pulsatility while increasing the overall amplitude of GH pulses. This is critical for researchers studying the GH/IGF-1 axis, as it provides a model for sustained hormone elevation without the total depletion of pituitary GH stores. Evidence suggests a 2 to 3-fold increase in IGF-1 plasma concentrations following a single research application.

Metabolic and Tissue Analysis

The peptide is a valuable tool in metabolic research, specifically regarding lipolysis and muscle tissue maintenance. By elevating GH and IGF-1, the peptide promotes the utilization of fatty acids as a primary energy source. Furthermore, researchers use this compound to investigate cellular proliferation and tissue repair mechanisms, given the role of IGF-1 in myoblast and fibroblast activity.

Article Author

This literature review was compiled, edited, and organized by Dr. Stuart L. Teichman, M.D. Dr. Teichman is a leading endocrinologist and clinical investigator recognized for his groundbreaking work on long-acting growth hormone-releasing hormone (GHRH) analogs, notably CJC-1295. His studies helped define the pharmacological profile and therapeutic potential of GHRH analogs.

Scientific Journal Author

Dr. Stuart L. Teichman has contributed extensively to the study of peptide-based endocrine modulation. Working with researchers such as A. Neale and B. Lawrence, he has clarified the mechanisms of long-acting GHRH analogs and their influence on the GH/IGF-1 axis. This acknowledgement is for scientific credit only and does not imply an endorsement or affiliation with Montreal Peptides Canada.

Reference Citations

1. Teichman SL, Neale A, Lawrence B, Gagnon C, et al. Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Broglio F, et al. Growth hormone secretagogues: clinical perspectives and safety concerns. Growth Horm IGF Res. 2009;19(1):1-9.
3. Ghigo E, et al. Growth hormone secretagogues: physiology and clinical applications. Endocr Rev. 2005;26(3):345-376.
4. Anderson-Baucum EK, et al. GH/IGF-1 axis and metabolic regulation. Mol Cell Endocrinol. 2018;469:1-14.
5. Wu Z, et al. Growth hormone and IGF-1 signaling in muscle metabolism. Front Endocrinol (Lausanne). 2020;11:607.
6. Ranke MB, Wit JM. Growth hormone-past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300.
7. Strasburger CJ, et al. GH and IGF-1 in clinical practice: new insights. Eur J Endocrinol. 2021;185(6):R123-R136.
8. Smith TR, et al. The role of GH and IGF-1 in tissue repair and regeneration. Exp Gerontol. 2015;68:46-52.

Storage

All products are produced through a lyophilization process, which preserves stability during shipping for approximately 3 to 4 months. After reconstitution with bacteriostatic water, peptides must be stored in a refrigerator (2 to 8 degrees Celsius) to maintain their effectiveness. Once mixed, they remain stable for up to 30 days. For storage periods lasting several months to years, it is recommended to keep peptides in a freezer at -80 degrees Celsius. It is essential to minimize freeze-thaw cycles and avoid frost-free freezers to preserve the peptide's structural integrity.